CHICAGO — In this video, Sandra Mazzoni, DO, discusses the use of minimal residual disease, or MRD, testing in multiple myeloma.
“There’s a lot of hot topics right now in myeloma in general,” Mazzoni, hematologist with the Cleveland Clinic, said.
She highlighted updates using MRD testing as a surrogate marker in clinical trials. The findings were presented at ASCO Annual Meeting.
“I do think those are eventually going to be practice changing cause [sic] right now, there’s really no standardization for MRD testing in multiple myeloma,” Mazzoni said.
